| Symbol | Name | Last Close | Mkt Cap | DailyStocks' Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
|
Vote Now! Wednesday’s Close |
|---|---|---|---|---|---|
| REGN | Regeneron Pharmaceuticals, Inc. | $386.665 | $41.78B | Downtrend |
Biotech Stock Roundup: ALXN on Acquisition Spree, FDA Nod for REGN, AMGN Drugs
http://www.zacks.com/stock/news/326050/biotech-stock-roundup-alxn-on-acquisition-spree-fda-nod-for-regn-amgn-drugs?cid=CS-ZC-FT-326050
Oct 03, 2018 - The biotech sector grabs headlines this week with FDA approvals plus licensing and acquisition pacts.
0
Cancer Investing Highlight: Another One Joins The Big Immunotherapy Contest
https://seekingalpha.com/article/4209286-cancer-investing-highlight-another-one-joins-big-immunotherapy-contest?source=feed_sector_healthcare
Oct 02, 2018 - Regeneron is part of a pack of new checkpoint inhibitor developers in solid tumor oncology.Their entry to the PD-1 space recently was approved for a new indication in the field.What does it mean for t
0
Sanofi/Regeneron's Cemiplimab Wins FDA Nod for Skin Cancer
http://www.zacks.com/stock/news/325705/sanofi-regenerons-cemiplimab-wins-fda-nod-for-skin-cancer?cid=CS-ZC-FT-325705
Oct 01, 2018 - Sanofi (SNY)/Regeneron's (REGN) anti- PD-1 drug cemiplimab wins FDA approval for a type of skin cancer.
0
With life-threatening food allergies on the rise, drug companies ramp up new approaches
https://www.cnbc.com/2018/09/27/with-food-allergies-on-the-rise-drug-companies-ramp-up-new-approaches.html
Sep 27, 2018 - Allergies are on the rise and researchers are trying new methods to help combat potentially life threatening reactions.
0
FDA Lifts Clinical Hold on Sarepta's DMD Gene Therapy Program
http://www.zacks.com/stock/news/324777/fda-lifts-clinical-hold-on-sareptas-dmd-gene-therapy-program?cid=CS-ZC-FT-324777
Sep 25, 2018 - The FDA has lifted clinical hold on Sarepta's (SRPT) clinical study evaluating the Duchenne muscular dystrophy micro-dystrophin gene therapy program. The clinical hold was placed in July by the FDA.
0
CHMP Reconfirms Negative Opinion for Sarepta's Exondys
http://www.zacks.com/stock/news/324582/chmp-reconfirms-negative-opinion-for-sareptas-exondys?cid=CS-ZC-FT-324582
Sep 24, 2018 - The CHMP re-confirmed the negative opinion for Sarepta's (SRPT) Exondys, which is developed to treat individuals who have a specific type of Duchenne muscular dystrophy.
0
Novartis Gets Positive CHMP Opinion for Drugs, Biosimilar
http://www.zacks.com/stock/news/324579/novartis-gets-positive-chmp-opinion-for-drugs-biosimilar?cid=CS-ZC-FT-324579
Sep 24, 2018 - Novartis (NVS) gets positive CHMP opinion for a label expansion of Gilenya, gene therapy, and a biosimilar of Neulasta.
0
The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Celgene, Sanofi and Gilead Sciences
http://www.zacks.com/stock/news/323964/the-zacks-analyst-blog-highlights-regeneron-pharmaceuticals-celgene-sanofi-and-gilead-sciences?cid=CS-ZC-FT-323964
Sep 20, 2018 - The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Celgene, Sanofi and Gilead Sciences
0
Eylea Competition Coming But Pipeline Could Maintain Growth For Regeneron
https://seekingalpha.com/article/4207219-eylea-competition-coming-pipeline-maintain-growth-regeneron?source=feed_sector_healthcare
Sep 19, 2018 - Eylea represents a significant portion of revenue and will face upcoming competition, which could slow Regeneron sales growth over the coming years.Eylea recently received approval for a 12 week dose,
0
GameStop's Fundamentals Are Declining - Cramer's Lightning Round (9/18/18)
https://seekingalpha.com/article/4207068-gamestops-fundamentals-declining-cramers-lightning-round-9-18-18?source=feed_tag_cramers_picks
Sep 19, 2018 - Regeneron and Amgen are better picks than Biogen.The refiners are doing well.Book profits on Liberty Oilfield Services.
0
Page 1>
Related Companies
| Name | Exchange | Price | Mkt Cap | |
| ZTS | Zoetis Inc. | NYSE | $88.3 | $42.55B |
| VRTX | Vertex Pharmaceuticals Incorporated | NASDAQ | $175.8 | $44.93B |
| SHPG | Shire plc | NASDAQ | $176.25 | $46.08B |
| ALXN | Alexion Pharmaceuticals, Inc. | NASDAQ | $117.77 | $26.25B |
| TEVA | Teva Pharmaceutical Industries Limited | NYSE | $23.43 | $23.86B |